Boehringer Ingelheim Vetmedica - Cydectin - Ownership and Business Overview

Life ScienceCompany

Boehringer Ingelheim Vetmedica - Cydectin Ownership

Who owns Boehringer Ingelheim Vetmedica - Cydectin?

Boehringer Ingelheim Vetmedica - Cydectin is owned by Bayer AG. It was acquired on January 4, 2017.

Boehringer Ingelheim Vetmedica - Cydectin Business Overview

Where is Boehringer Ingelheim Vetmedica - Cydectin headquartered?

Boehringer Ingelheim Vetmedica - Cydectin is headquartered in St. Joseph, Montana.

What sector is Boehringer Ingelheim Vetmedica - Cydectin in?

Boehringer Ingelheim Vetmedica - Cydectin is a life science company.

Life Science M&A Summary in 2017

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2017. The largest life science acquisition in 2017 was Actelion - which was acquired by Johnson & Johnson for $30.0B.

Join Mergr to view all 248 acquisitions of life science companies in 2017, including 23 acquisitions by private equity firms, and 225 by strategics.

Boehringer Ingelheim Vetmedica, Inc. - Cydectin

St. Joseph, Montana 64506
United States,

Boehringer Ingelheim Vetmedica, Inc. - Cydectin includes CYDECTIN Pour-On, CYDECTIN Injectable and CYDECTIN Oral Drench. These endectocides with the active ingredient moxidectin offer persistent killing of internal parasites at multiple stages, including the most economically devastating parasite, Ostertagia ostertagi (brown stomach worm) and controls external parasites including lice, grubs and psoroptic mange mites on beef and dairy cattle.


 Subscribe to unlock this and 201,598
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.